Literature DB >> 8030282

Transcription-modulatory activity of full-length E6 and E6*I proteins of human papillomavirus type 16.

H Shirasawa1, M H Jin, K Shimizu, N Akutsu, Y Shino, B Simizu.   

Abstract

The E6 gene of human papillomavirus type 16 (HPV16) has the potential to encode full-length as well as truncated E6 proteins (E6*I and E6*II) by alternative splicings. Spliced ORF E6*I is considered to facilitate the translation of the neighboring E7 ORF; however, the putative E6*I protein is suspected to be functionless. In this study, the transcription-modulatory functions of full-length E6 and E6*I proteins were examined using cDNAs from a cervical carcinoma cell line. E6*I cDNA was able to trans-activate the autologous P97 promoter and the heterologous adenovirus E2 promoter. Full-length E6 was found to trans-activate the heterologous promoter, but repress transcription from the autologous P97 promoter. The transcription-modulatory functions of full-length E6 and E6*I proteins suggested that transcriptional regulation of HPVs associated with mucosal malignant lesions is complex.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8030282     DOI: 10.1006/viro.1994.1452

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Destabilization of TIP60 by human papillomavirus E6 results in attenuation of TIP60-dependent transcriptional regulation and apoptotic pathway.

Authors:  Sudhakar Jha; Scott Vande Pol; Nilam Sanjib Banerjee; Arun Brendan Dutta; Louise T Chow; Anindya Dutta
Journal:  Mol Cell       Date:  2010-06-11       Impact factor: 17.970

3.  Human papillomavirus type 16 E6 protein transcriptionally modulates fibronectin gene expression by induction of protein complexes binding to the cyclic AMP response element.

Authors:  Y Shino; H Shirasawa; T Kinoshita; B Simizu
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Temperature-sensitive retinoid isomerase activity of RPE65 mutants associated with Leber Congenital Amaurosis.

Authors:  Songhua Li; Jane Hu; Robin J Jin; Ashok Aiyar; Samuel G Jacobson; Dean Bok; Minghao Jin
Journal:  J Biochem       Date:  2015-03-09       Impact factor: 3.387

5.  Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.

Authors:  L V Ronco; A Y Karpova; M Vidal; P M Howley
Journal:  Genes Dev       Date:  1998-07-01       Impact factor: 11.361

7.  Differential localization of HPV16 E6 splice products with E6-associated protein.

Authors:  Kulthida Vaeteewoottacharn; Siriphatr Chamutpong; Mathurose Ponglikitmongkol; Peter C Angeletti
Journal:  Virol J       Date:  2005-06-16       Impact factor: 4.099

8.  Inactivation of p53 rescues the maintenance of high risk HPV DNA genomes deficient in expression of E6.

Authors:  Laurel D Lorenz; Jessenia Rivera Cardona; Paul F Lambert
Journal:  PLoS Pathog       Date:  2013-10-24       Impact factor: 6.823

9.  Rescue of enzymatic function for disease-associated RPE65 proteins containing various missense mutations in non-active sites.

Authors:  Songhua Li; Tadahide Izumi; Jane Hu; Heather H Jin; Ahmed-Abdul A Siddiqui; Samuel G Jacobson; Dean Bok; Minghao Jin
Journal:  J Biol Chem       Date:  2014-05-21       Impact factor: 5.157

Review 10.  Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer.

Authors:  Hun Soon Jung; Nirmal Rajasekaran; Woong Ju; Young Kee Shin
Journal:  J Clin Med       Date:  2015-05-21       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.